Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8679282 | Thrombosis Research | 2018 | 5 Pages |
Abstract
The “HERDOO2 rule” is the only prospectively validated clinical decision rule that can be used to identify low-risk women with unprovoked venous thrombosis who can safely discontinue anticoagulants. An important implementation issue is whether any commercial DD assay can be used in the HERDOO2 rule, and at what cut-point. Our analysis shows that the HemosIL®, Innovance®, Liatest® and Tina-quant® DD assays should not be used in the “HERDOO2” rule due to poor concordance with the VIDAS® DD assay and unacceptable misclassification of women at high and low risk of recurrent venous thrombosis.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Marc A. Rodger, Gregoire Le Gal, Nicole J. Langlois, Barron Gin, Ranjeeta Mallick, Antonio Giulivi, Marisa Freedman, Michael J. Kovacs, REVERSE II investigators REVERSE II investigators,